Linkedin
RLS logo_header
Linkedin

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics

Repare Therapeutics announced that following the announcement on November 14, 2025 of the entering into of a definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. a non-profit biotechnology company, pursuant to which Xeno will acquire all of the issued and outstanding common shares of Repare, certain entities affiliated with BVF Partners L.P., Blue Owl Healthcare Opportunities, and certain entities affiliated with OrbiMed have each entered into a support and voting agreement pursuant to which they have agreed to vote their Common Shares in favor of the special resolution approving the Transaction.

Read the full story on "Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics"

Share:

More News

TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors

“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer

“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in

Taletrectinib (IBTROZI®) Added as Recommended Option to NCCN Guidelines for CNS Cancers

“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of

First Patient Dosed in Ph 1/2 Study of MT-304 in HER2-Positive Solid Tumors

Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo